Evidence map

ArticleMetabolism open2026

Baseline metabolite profiles predict the glucose-lowering efficacy of exenatide in patients with type 2 diabetes.

Yunyi Le et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 41799733